Melanoma and Vitiligo: In Good Company

Research output: Contribution to journalReview articlepeer-review


Cutaneous melanoma represents the most aggressive form of skin cancer, whereas vitiligo is an autoimmune disorder that leads to progressive destruction of skin melanocytes. However, vitiligo has been associated with cutaneous melanoma since the 1970s. Most of the antigens recognized by the immune system are expressed by both melanoma cells and normal melanocytes, explaining why the autoimmune response against melanocytes that led to vitiligo could be also present in melanoma patients. Leukoderma has been also observed as a side effect of melanoma immunotherapy and has always been associated with a favorable prognosis. In this review, we discuss several characteristics of the immune system responses shared by melanoma and vitiligo patients, as well as the significance of occurrence of leukoderma during immunotherapy, with special attention to check-point inhibitors.

Original languageEnglish
JournalInternational Journal of Molecular Sciences
Issue number22
Publication statusPublished - Nov 15 2019


Dive into the research topics of 'Melanoma and Vitiligo: In Good Company'. Together they form a unique fingerprint.

Cite this